Does the Purification Rundown actually make people healthier?

Reducing a laboratory measurement is interesting. Feeling better is more important.

If the Hubbard protocol reduced PCB concentrations but nobody experienced any improvement in life, it would remain an intriguing toxicology experiment. That isn’t what happened.

Across several decades, very different groups undergoing Hubbard-style treatment have reported improvements in physical health, mental health, sleep, memory, attention, fatigue, pain, energy, neurotoxicity symptoms, quality of life, and everyday functioning.

Not everybody improves. Not every measurement changes. The research is not as large as it ought to be. But the recurring clinical pattern is difficult to ignore.

1982: the first large clinical report

The first major published evaluation appeared in Medical Hypotheses in 1982. D.W. Schnare and colleagues evaluated 103 volunteers with histories involving recreational drugs, medications, occupational chemicals, and environmental exposures.

Among participants with elevated blood pressure, average reductions were approximately 30.8 mmHg systolic and 23.3 mmHg diastolic. Mean cholesterol fell about 19.5 mg/dL.

Psychological testing also changed. The reported mean increase on the Wechsler Adult Intelligence Scale was 6.7 points. Medical complications were reported in fewer than three percent of participants.

This was an early observational evaluation rather than a modern randomized trial. Its significance is that the first large cohort did not merely report sweating or flushing. Researchers documented substantial changes in physical and psychological measures.

1985: 120 chemically exposed patients

Occupational physician David Root and colleagues subsequently applied Hubbard’s system to people with chronic chemical-exposure symptoms.

The resulting 1985 paper is sometimes cited as though it were an ordinary peer-reviewed journal article. It wasn’t. The EPA HERO database classifies it as a technical report, published in the Proceedings of the National Conference on Hazardous Wastes and Environmental Emergencies.

The report described preliminary data from 120 patients who completed the program after exposure to substances including pesticides, solvents, and other bioaccumulative chemicals. The authors reported improvement in 14 of 15 symptom categories.

That deserves to be read as what it is: a substantial clinical series and historically important occupational-medicine report, but not a randomized controlled trial.

Firefighters and brain function

One of the more interesting later studies involved firefighters exposed to PCBs and combustion products following a transformer fire. Fourteen exposed firefighters underwent neuropsychological testing and were compared with fourteen non-exposed firefighters.

The exposed group performed worse in areas including memory, cognition, and perceptual-motor function.

Following approximately two to three weeks of medically supervised diet, exercise, and sauna treatment, significant improvements appeared on several tests involving verbal memory, visual memory, block design, embedded figures, and Trail Making.

Not everything improved. Reaction time, balance, and some mood/fatigue measures did not show comparable changes.

That’s useful information. The intervention produced a pattern rather than a miraculous improvement in every possible measurement.

Police officers who had become chronically sick

The Utah Meth Cops Project gives us one of the clearest pictures of what these clinical changes can mean in ordinary life.

Sixty-nine police officers with persistent symptoms after occupational exposure to methamphetamine laboratories entered a Hubbard-derived program. The study was an uncontrolled retrospective medical-chart evaluation, so it cannot by itself prove causality. But the before-and-after differences were large.

The officers reported an average 9.3 days of poor physical health per month before treatment. At completion, 1.8 days.

• Poor mental-health days fell: 6.3 → 1.4
• Days on which poor health limited normal activities: 4.3 → 0.2
• Sick days: 2.0 → 0.3
• Average sleep increased: 5.8 → 7.6 hours per night

And mean neurotoxicity scores among those with paired data fell: 65.5 → 14.6. All of these changes were statistically significant in the reported analyses.

Those aren’t merely abstract questionnaire movements. For the person experiencing them, that is potentially the difference between being chronically impaired and getting much of ordinary life back.

Most of the officers finished

The completion rate was 92.8 percent. Sixty-four of the 69 officers completed the program. Mean treatment duration among completers was about 33 days.

The protocol included gradual exercise, nutritional support, moderate-temperature sauna, regular breaks, and fluid/electrolyte replacement.

That matters because the regimen is demanding. Most of these symptomatic officers nevertheless completed it.

A 109-person substance-use cohort

In 2018, Richard Lennox and Marie Cecchini-Sternquist published a prospective evaluation of 109 sequential participants entering the sauna-detoxification component of a residential substance-use treatment program.

The reported completion rate was 99 percent. There were no reported cases of dehydration, overhydration, or heat illness. Physical and mental SF-36 scores improved significantly during the regimen.

The participants’ own open-ended descriptions are particularly interesting. At completion:

• 68% mentioned improved energy
• 51% described clearer thinking or mental acuity
• 45% described greater emotional stability
• 31% reported improved fitness, senses, or fewer physical symptoms
• 31% described a more positive outlook
• 28% said they now slept well
• 26% said they no longer craved drugs or alcohol
• 25% described themselves as happy
• and 22% described themselves as “back to myself.”

Those responses are one reason the clinical literature feels rather different when read closely than when summarized simply as “limited evidence.”

People weren’t merely completing the program. Many believed something important had changed.

Funding transparency

There is an important disclosure attached to the 2018 study. The evaluation was funded through grants from Narconon International to Chestnut Health Systems.

The authors declared no conflict of interest, but the funding relationship is directly relevant given Narconon’s use of Hubbard’s methods and should be visible to readers.

Funding does not make results disappear. It tells us why independent replication matters.

Then researchers randomized it

For decades, the obvious challenge to this body of literature was: Where is the randomized trial? In 2019, researchers published one.

The participants were veterans with Gulf War illness, a persistent multisymptom condition following a war characterized by complex potential exposures including pesticides, pyridostigmine bromide, oil-fire smoke, nerve-agent exposure, and other chemicals.

Thirty-two veterans entered a randomized wait-list-controlled pilot. 22 were assigned to immediate treatment. 10 entered the wait-list condition.

The daily four- to six-week intervention included immediate-release crystalline nicotinic acid, 20–30 minutes of aerobic exercise, 2–4 hours intermittent sauna, electrolytes, polyunsaturated oils, and vitamin/mineral supplementation.

All 32 completed the randomized portion. Twenty-one completed three-month follow-up.

What changed?

Across quality-of-life, pain, and fatigue outcomes, 11 of 16 measures improved.

The mean SF-36 physical-component score after intervention was 6.9 points above the wait-list condition, although its 95% confidence interval of −0.3 to 14.2 crossed zero.

Most improvements were retained three months later. No serious adverse events occurred.

This is a pilot. It was intended to establish feasibility, safety, and whether there was enough efficacy signal to justify larger research. There was.

The neuropsychological follow-up

A second paper published in Military Medicine in 2021 examined psychological and neuropsychological results from the same Gulf War trial. It should therefore not be counted as an independent replication. But it adds detail.

The authors reported improvement in 16 of 19 psychological and neuropsychological measures at the seven-day assessment, with 13 improvements remaining stable at three months.

Improvements involved areas including anxiety, depression, hostility, somatization, memory, attention, mental flexibility, motor function, and processing tasks.

Who funded the Gulf War research?

Unlike some of the earlier Hubbard-related literature, the Gulf War trial was supported through the U.S. Department of Defense Gulf War Illness Research Program.

Investigators were affiliated with institutions including the University of Toronto, Russell Sage College, the University at Albany, and St. Michael’s Hospital.

The treatment was delivered using an established Hubbard-derived clinical program.

This makes the trial especially useful. It is not merely another internal Narconon evaluation. Nor is it a massive definitive independent replication. It sits somewhere more interesting in between: a government-funded academic pilot testing an established real-world treatment.

Look at the populations together

Now put the groups beside each other. Mixed-exposure participants. Industrial chemical patients. PCB-exposed firefighters. Police officers repeatedly exposed to meth labs. People recovering from drugs. World Trade Center responders. Gulf War veterans.

Very different populations. Yet similar improvements keep appearing:

• less fatigue
• clearer thinking
• better memory
• better sleep
• fewer physical symptoms
• better emotional functioning
• better quality of life
• more energy
• greater capacity to function normally.

That repetition is the interesting part.

Does improvement prove Hubbard’s complete theory?

No. And it doesn’t have to.

The protocol simultaneously changes exercise, heat exposure, sleep, food, hydration, electrolytes, daily routine, niacin pharmacology, chemical body burden, and something the phrase “micronutrient intake” understates: a deliberately escalating pharmacological nutrient network.

Niacin is being used at drug-like doses. Thiamine and other B vitamins rise far beyond ordinary dietary intake. Vitamin C and E rise sharply. Calcium, magnesium, iron, zinc, manganese, copper, iodine, and other minerals scale upward as a coordinated profile. Oils and lecithin alter the lipid side of the intervention.

That creates several plausible pathways for improvement at the same time: lower chemical burden, altered lipid metabolism, correction of latent deficiencies, pharmacological nutrient effects, improved neuromuscular stability, heat adaptation, exercise, better sleep, and repeated recovery.

That may be a feature rather than a flaw. Hubbard didn’t design a single-target pharmaceutical. He designed a systems intervention, and the health outcomes may reflect several active parts working together.

What we can reasonably say

We know that people in multiple clinical populations improved while undergoing Hubbard-style programs. We know some improvements were large. We know some were measured objectively with cognitive testing. We know the randomized Gulf War pilot produced a positive enough signal to warrant further work. We know some improvements persisted months later.

And separately, we know from toxicant-measurement studies that body burdens of certain persistent compounds can decline during similar interventions.

What remains uncertain is exactly why every improvement occurs. That is a mechanistic limitation. It is not evidence that the improvements didn’t happen.

The practical conclusion

If someone with chronic problems following a significant chemical or drug exposure asks, “Has anyone like me ever done this and actually gotten better?” the answer is: Yes.

Police officers did. Firefighters did. Chemically exposed workers did. People in substance-use recovery did. Gulf War veterans did.

Not everyone. Not every symptom. Not in every measurement. But often enough—and sometimes dramatically enough—that the protocol deserves considerably more interest than it usually gets.

The scientific question is increasingly not simply: “Does anything happen?” It is: Who benefits most, why do they benefit, and how can the intervention be made more efficient and more precise?

Research & references

• Schnare DW, Denk G, Shields M, Brunton S. “Evaluation of a Detoxification Regimen for Fat Stored Xenobiotics.” Medical Hypotheses. 1982;9(3):265–282.
• Root DE, Katzin DB, Schnare DW. “Diagnosis and Treatment of Patients Presenting Subclinical Signs and Symptoms of Exposure to Chemicals Which Bioaccumulate in Human Tissue.” Proceedings of the National Conference on Hazardous Wastes and Environmental Emergencies. Cincinnati, Ohio, May 14, 1985:150–153. Technical report/conference proceedings.
• Kilburn KH, Warsaw RH, Shields MG. “Neurobehavioral Dysfunction in Firemen Exposed to Polychlorinated Biphenyls (PCBs): Possible Improvement after Detoxification.” Archives of Environmental Health. 1989;44(6):345–350. doi:10.1080/00039896.1989.9935904.
• Ross GH, Sternquist MC. “Methamphetamine Exposure and Chronic Illness in Police Officers: Significant Improvement with Sauna-Based Detoxification Therapy.” Toxicology and Industrial Health. 2012;28(8):758–768. doi:10.1177/0748233711425070.
• Lennox RD, Cecchini-Sternquist M. “Safety and Tolerability of Sauna Detoxification for the Protracted Withdrawal Symptoms of Substance Abuse.” Journal of International Medical Research. 2018;46(11):4480–4499. doi:10.1177/0300060518779314. Funded by grants from Narconon International to Chestnut Health Systems.
• Kerr K, Morse G, Graves D, Zuo F, Lipowicz A, Carpenter DO. “A Detoxification Intervention for Gulf War Illness: A Pilot Randomized Controlled Trial.” International Journal of Environmental Research and Public Health. 2019;16(21):4143. doi:10.3390/ijerph16214143.
• Graves DF, Morse GS, Kerr K, Carpenter DO. “A Pilot Study to Examine Psychological and Neuropsychological Outcomes and a Novel Detoxification Program for Gulf War Illness.” Military Medicine. 2021;186(Suppl 1):205–213. doi:10.1093/milmed/usaa486.